Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ known ✓ | Q05513 | 1/20 | 0.33 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.32 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.32 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.32 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.32 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.32 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.32 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL992776 | 1.00 | CYP3A4 (0.46) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| Hydrochloric Acid SCHEMBL134929 | 1.00 | CYP3A4 (0.46) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| Hydrochloric Acid SCHEMBL28335260 | 0.98 | ALDH1A1 (0.43) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| Hydrochloric Acid SCHEMBL28663126 | 0.98 | ALDH1A1 (0.43) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| Hydrochloric Acid SCHEMBL3504243 | 0.98 | ALDH1A1 (0.43) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| SCHEMBL30272720 | 0.98 | TDP1 (0.48) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| SCHEMBL5983370 | 0.98 | TDP1 (0.48) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| SCHEMBL21373 | 0.98 | TDP1 (0.48) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| SCHEMBL3507048 | 0.95 | TDP1 (0.46) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| Water SCHEMBL7066183 | 0.95 | TDP1 (0.46) | CYP3A4ALDH1A1TDP1TP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805576-A | anti-VISTA antibodies and fragments | 詹森药业有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-107922497-B | anti-VISTA antibodies and fragments | 詹森药业有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-2275117-B1 | GLP-1, exendin-4, peptide analogs and uses thereof | US GOVERNMENT (US) | 2016-10-26 | — | — | EP | disclosed |
| US-8853160-B2 | GLP-1, exendin-4, peptide analogs and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2014-10-07 | — | — | US | disclosed |
| CN-103169731-A | Methods of generating, repairing and/or maintaining connective tissue in vivo | ANGIOBLAST SYSTEMS INC | 2013-06-26 | — | — | CN | disclosed |
| CN-101827603-B | Method for generating, repairing and/or maintaining connective tissue in vivo | ANGIOBLAST SYSTEMS INC | 2013-03-06 | — | — | CN | disclosed |
| US-20120329715-A1 | GLP-1, EXENDIN-4, PEPTIDE ANALOGS AND USES THEREOF | The Gov. of the US, as represented by the Secretary, Dept. of Health & Human Services (US) | 2012-12-27 | — | — | US | disclosed |
| US-8278272-B2 | GLP-1, exendin-4, peptide analogs and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2022505-B1 | GLP-1, exendin-4, peptide analogs and uses thereof | US GOV HEALTH & HUMAN SERV (US) | 2011-12-14 | — | — | EP | disclosed |
| EP-2275117-A1 | GLP-1, exendin-4, peptide analogs and uses thereof | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20030199448-A1 | Treatment of skin conditions | UNIVERSITY COLLEGE CARDIFF CONSULTANTS, LTD. (GB) | 2003-10-23 | — | — | US | disclosed |
| US-20030170807-A1 | Nucleic acid molecule encoding homer 1b protein | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2003-09-11 | — | — | US | disclosed |
| WO-2003011892-A2 | GLP-1 EXENDIN-4 PEPTIDE ANALOGS AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020147141-A1 | Treatment of skin conditions | GUMBLETON MARK (GB) | 2002-10-10 | — | — | US | disclosed |
| EP-1245237-A1 | Treatment of skin conditions | University College Cardiff Consultants Limited (GB) | 2002-10-02 | — | — | EP | disclosed |
| EP-1105734-A2 | HOMER INTERACTING PROTEINS | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000011204-A2 | HOMER INTERACTING PROTEINS | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0105614-B1 | METHOD FOR DISCRIMINATING BETWEEN UNSTAINED AND ABSORBING DYE STAINED CELLS | ORTHO DIAGNOSTIC SYSTEMS INC. (US) | 1988-09-07 | — | — | EP | disclosed |
| US-4492752-A | Method for discriminating between unstained and absorbing dye stained cells | ORTHO DIAGNOSTICS SYSTEMS INC. (US) | 1985-01-08 | — | — | US | disclosed |
| EP-0105614-A2 | Method for discriminating between unstained and absorbing dye stained cells | ORTHO DIAGNOSTIC SYSTEMS INC. (US) | 1984-04-18 | — | — | EP | disclosed |